Table 5

Impact of marker status on clinical and pathological tumor features in TACE treated HCC
EpCAM CD133
Low (n = 6) High (n = 10) P Low (n = 4) High (n = 12) P
Age (year) 58(53–65) 56(48–68) 0.236 52(48–57) 58(49–68) 0.070
Gender (F/M) 1/5 1/9 0.696 0/4 2/12 0.383
AFP (ng/ml) 1333(4–7254) 256(3–2000) 0.289 297(8–43) 870(3–7254) 0.177
Interval between 189(82–345) 224(73–337) 0.479 260(188–327) 194(73–377) 0.217
TACE and Tx (days)
More than one TACE 1/6 3/10 0.639 2/4 2/12 0.329
Tumor Size (mm) 45(25–76) 34(20–55) 0.181 36(32–40) 39(20–76) 0.744
Tumor differentiation 0.024 0.834
Well 0 1 0 1
Moderately 6 3 3 8
Poor 0 6 1 3
TNM Stages 0.302 0.248
I 4 4 1 7
II 2 6 3 5

Zeng et al.

Zeng et al. BMC Cancer 2012 12:584   doi:10.1186/1471-2407-12-584

Open Data